PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting
Publication: ASBRS 2025 Authors: Thompson et al. Title: Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting Introduction: Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and Read More
High Concordance of 70-Gene Recurrence Risk Signature and 80-Gene Molecular Subtyping Signature Between Core Needle Biopsy and Surgical Resection Specimens in Early-Stage Breast Cancer
Publication: J Surg Oncol. 2022;125:596โ602. Authors: Jennifer A. Crozier MD | Julie Barone DO | Pat Whitworth MD |Abraham Cheong MD | Robert Maganini MD | Jose Perez Tamayo MD | Patricia Dauer PhD | Shiyu Wang MS | William Audeh MD | Annuska M. Glas PhD Title: High Read More
Successful Unconventional Precision Treatment of Inflammatory Hormone Receptor-Positive Breast Cancer Guided by Molecular Profiling
Publication: npj Precision Oncology | (2025) 9:63 Authors: Jailan Elayoubi , Yu Zong & Erich J. Schwartz Title: Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling Abstract: We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth Read More
Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX
Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce OโShaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrintยฎ Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: โข Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More
Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers โ A FLEX sub study
Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Joyce O'Shaughnessy2, Adam Brufsky3, Reshma L. Mahtani4, Kent Hoskins5, Hannah Linden6, Nina D'Abreo7, Sahra Uygun8, Lavanya Samraj8, William Audeh8 University of Colorado Anschutz Medical Campus, Aurora CO 2. Baylor University Medical Center, Dallas, TX 3. University of Pittsburgh Medical Center Read More
Survival Outcomes for Patients With Invasive Lobular Cancer by MammaPrint: Results From the MINDACT Phase III Trial
Publication: European Journal of Cancer 217 (2025) 115222 Authors: O. Metzger Filho, F. Cardoso, C. Poncet, C. Desmedt, S. Linn, J. Wesseling,F. Hilbers, S. Delaloge,ย J.-Y. Pierga, E. Brain, S. Vrijaldenhoven, P.A. Neijenhuisj, E.J.Th Rutgers, M. Piccart, L.J. van โt Veerl, G. Viale Title: Survival outcomes for patients with Read More
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King
Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce OโShaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision MedicineโBiology Is Still King Abtract: Clinical Read More
